Risk Factors for Parkinson's Disease Dementia

doi:10.3877/cma.j.issn.2095-8757.2016.01.005

Abstract

Abstract:

Parkinson's disease (PD) is a common idiopathic neurodegenerative disease in elderly population. Parkinson's disease dementia (PDD) is one of the most common non-motor symptoms in PD patients. PDD reduces PD patients' quality of life and severely influence prognosis of Parkinson patients. Common risk factors for PDD include demographic factors, way of living, motor symptoms, non-motor symptoms, biological markers and imaging factors. We summarized recent study results on risk factors for PDD.

Key words: Parkinson's disease, Parkinson's disease dementia, Risk factors

Yaqian Xu, Huifang Shang. Risk Factors for Parkinson's Disease Dementia[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2016, 03(01): 21-25.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2016.01.005

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2016/V03/I01/21

References 52

[1]	Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease[J].Mov Disord, 2005, 20(10): 1255-1263.
[2]	Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom[J]. Mov Disord, 2004, 19(9): 1043-1049.
[3]	Athey RJ, Porter RW, Walker RW. Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R)[J]. Age Ageing, 2005, 34(3): 268-273.
[4]	de Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study[J]. Arch Neurol, 2005, 62(8):1265-1269.
[5]	Wang Q, Zhang Z, Li L, et al. Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors[J]. Clin Interv Aging, 2014, 9: 275-281.
[6]	Hely MA, Morris JG, Reid WG, et al. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years[J]. Mov Disord, 2005, 20(2): 190-199.
[7]	Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years[J]. Mov Disord, 2008, 23(6): 837-844.
[8]	Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study[J]. Arch Neurol, 2003, 60(3):387-392.
[9]	Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD[J].Neurology, 2002, 59(11): 1708-1713.
[10]	谭玉燕，陈生弟．帕金森病痴呆的临床特征及治疗进展[J]．中华神经科杂志，2006，39(6): 413-415.
[11]	陈晓春，叶钦勇．帕金森病痴呆的发病机制与治疗[J]．中国现代神经疾病杂志，2009，9(3): 221-223.
[12]	陈生弟，中华医学会神经病学分会帕金森病及运动障碍学组．中国帕金森病治疗指南(第二版)[J]．中华神经科杂志，2009，42(5): 352-355.
[13]	Zhou MZ, Gan J, Wei YR, et al. The association between non-motor symptoms in Parkinson's disease and age at onset[J]. Clin Neurol Neurosurg, 2013, 115(10): 2103-2107.
[14]	Hughes TA, Ross HF, Musan S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease[J]. Neurology, 2000, 54(8): 1596-602.
[15]	Marder K, Tang MX, Cote L, et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease[J]. Arch Neurol, 1995, 52(7): 695-701.
[16]	Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort[J]. J Neurol Neurosurg Psychiatry, 2013, 84(11): 1258-1264.
[17]	Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease[J]. Ann Neurol, 2007, 62(2): 145-153.
[18]	Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important[J]? Brain, 2011, 134(Pt 5): 1493-1505.
[19]	Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study[J]. Neurology, 2014, 83(14): 1253-1260.
[20]	Chen L, Yu C, Fu X, et al. Using the montreal cognitive assessment scale to screen for dementia in Chinese patients with Parkinson's disease[J]. Shanghai Arch Psychiatry, 2013, 25(5): 296-305.
[21]	Marder K, Flood P, Cote L, et al. A pilot study of risk factors for dementia in Parkinson's disease[J]. Mov Disord, 1990, 5(2): 156-61.
[22]	Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia[J]. Neurology, 1998, 50(4): 1141-1143.
[23]	Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging[J]. Neurology, 1997, 48(6): 1517-1521.
[24]	Maki PM, Henderson VM. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on[J]. Climacteric, 2012, 15(3): 256-62.
[25]	Zoccolella S, dell'Aquila C, Abruzzese G, et al. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia[J]. Mov Disord, 2009, 24(7): 1028-1033.
[26]	Glatt SL, Hubble JP, Lyons K, et al. Risk factors for dementia in Parkinson's disease: effect of education[J]. Neuroepidemiology, 1996, 15(1): 20-25.
[27]	Hu MT, Szewczyk-Krolikowski K, Tomlinson P, et al. Predictors of cognitive impairment in an early stage Parkinson's disease cohort[J]. Mov Disord, 2014, 29(3): 351-359.
[28]	Ebmeier KP, Calder SA, Crawford JR, et al. Clinical features predicting dementia in idiopathic Parkinson's disease: a follow-up study[J]. Neurology, 1990, 40(8): 1222-1224.
[29]	Levy G, Tang MX, Cote LJ, et al. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study[J]. Mov Disord, 2002, 17(2): 250-257.
[30]	Fitts W, Weintraub D, Massimo L, et al. Caregiver report of apathy predicts dementia in Parkinson's disease[J]. Parkinsonism Relat Disord, 2015, 21(8): 992-995.
[31]	Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia[J]. J Neurol, 2007, 254(1): 38-45.
[32]	Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease[J]. Mov Disord, 2006, 21(8): 1123-1130.
[33]	Lyros E, Messinis L, Papathanasopoulos P. Does motor subtype influence neurocognitive performance in Parkinson's disease without dementia? [J] Eur J Neurol, 2008, 15(3): 262-267.
[34]	Pedersen KF, Larsen JP, Tysnes OB, et al. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study[J]. JAMA Neurol, 2013, 70(5): 580-6.
[35]	Postuma RB, Bertrand JA, Montplaisir J, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study[J]. Mov Disord, 2012, 27(6): 720-726.
[36]	Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort[J]. Neurology, 2009, 73(18): 1469-1477.
[37]	Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease[J]. Neurology, 2010, 75(12): 1055-1061.
[38]	Compta Y, Pereira JB, Rios J, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study[J]. Parkinsonism Relat Disord, 2013, 19(8): 717-724.
[39]	Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study[J]. Lancet Neurol, 2011, 10(3): 230-40.
[40]	Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease[J].Ann Neurol, 2011, 69(4): 655-663.
[41]	俱西驰，屈秋民，王伟，等．血清尿酸水平与帕金森病认知功能障碍的关系[J]．南京医科大学学报(自然科学版)，2013，33(1): 59-61.
[42]	Andreadou E, Nikolaou C, Gournaras F, et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration[J]. Clin Neurol Neurosurg, 2009, 111(9): 724-728.
[43]	Gonzalez-Aramburu I, Sanchez-Juan P, Sierra M, et al. Serum uric acid and risk of dementia in Parkinson's disease[J]. Parkinsonism Relat Disord, 2014, 20(6): 637-639.
[44]	张玉虎，甘蓉，聂坤，等．帕金森病认知障碍与血尿酸水平的相关性分析[J]．国际神经病学神经外科学杂志，2013，40(3): 216-219.
[45]	Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease[J]. J Neurol, 2009, 256(3): 493-498.
[46]	Sidransky E, Lopez G. The link between the GBA gene and parkinsonism[J]. Lancet Neurol, 2012, 11(11): 986-998.
[47]	Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort[J]. Brain, 2013, 136(Pt 2): 392-399.
[48]	Duncan GW, Firbank MJ, O'Brien JT, et al. Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease[J]? Mov Disord, 2013, 28(4): 425-438.
[49]	Pan PL, Shi HC, Zhong JG, et al. Gray matter atrophy in Parkinson's disease with dementia: evidence from meta-analysis of voxel-based morphometry studies[J]. Neurol Sci, 2013, 34(5): 613-619.
[50]	Xu Y, Yang J, Hu X, et al. Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's disease[J]. J Neurol, 2016, Epub.
[51]	Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia[J]. Neuropsychopharmacology, 2013, 38(6): 938-949.
[52]	Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia[J].Neuroimage, 2008, 39(3): 1027-1033.

Please choose a citation manager

Content to export